secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269696
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences Q3 net loss $1.9M, cash $12.7M; cash runway through Q3 2026
--------------------------------------------------------------------------------

- Net loss for Q3 2025 was $1.9M ($1.77 per share) vs $2.2M ($40.15) in Q3 2024.
- Cash and equivalents $12.7M at Sept 30, 2025, up from $6.5M at Dec 31, 2024.
- Received $9.6M gross proceeds from warrant inducement in September 2025.
- Announced top-line results from PRIME clinical study; plans FDA meeting for Gemini registration path.
- Net cash used in operations $6.3M for 9 months 2025 vs $14.6M in same period 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000119312525269696/0001193125-25-269696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000119312525269696/revb-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer